Sibalyn1%

Sibalyn is a topical antimicrobial cream with the following established uses:

FDA-Approved / Established Use

• Adjunctive treatment for prevention and treatment of wound sepsis in patients with second-degree and third-degree burns. Sibalyn is used as an adjunct to, not a replacement for, other standard burn management measures (fluid resuscitation, debridement, nutritional support).

Guideline-Supported / Widely Accepted Use

• Topical prophylaxis against bacterial colonization and infection in other contaminated or infection-prone wounds (e.g. abrasions, minor cuts, pressure ulcers, leg ulcers) where clinically indicated, though evidence is strongest for burns.

Sibalyn is not effective against established deep-tissue or systemic infection and is not a substitute for systemic antibiotics when systemic infection is present.

Each gram of cream contains Silver Sulfadiazine USP 10 mg (1% w/w) in a water-miscible cream base.

Sibalyn is a topical sulfonamide antimicrobial agent formed by combining silver with sulfadiazine. It is formulated as a white to off-white, water-miscible cream applied directly to burn wounds and other infection-prone wounds to reduce bacterial colonization and the risk of wound sepsis. Sibalyn combines the broad antibacterial action of the silver ion with the antibacterial activity of the sulfonamide moiety.

Sibalyn belongs to the class of topical sulfonamide antimicrobial (antibacterial) agents used in burn and wound care.

The antibacterial action of Silver Sulfadiazine results from the combined effect of silver and the sulfadiazine moiety on the bacterial cell. Silver ions interact with bacterial DNA and cell membrane components, producing structural and functional changes in the cell wall and envelope that lead to bacterial cell death; only a small amount of silver is released to be bactericidal. The sulfadiazine component contributes bacteriostatic activity by interfering with bacterial folic acid synthesis. Silver Sulfadiazine has a broad spectrum of activity against many gram-negative and gram-positive bacteria, as well as some yeasts (including Candida albicans). Systemic absorption of sulfadiazine can occur, particularly with extensive burn surface area treatment, with plasma concentrations occasionally reaching therapeutic sulfonamide levels; urinary excretion of absorbed sulfadiazine ranges from about 60-85%.

For external/topical use only on the skin. Cleanse and debride the wound before each application using aseptic technique. Apply Sibalyn with a sterile gloved hand or sterile applicator. Cover with a dressing as directed by the treating physician. Avoid contact with eyes and mucous membranes.

Sibalyn has the following clinically significant interactions:

• Topical enzymatic debriding agents (e.g. collagenase, papain-urea): silver may inactivate these enzymes, reducing their debriding effect; avoid concurrent use on the same area.
• Cimetidine: concurrent use with Sibalyn has been associated with an increased incidence of leukopenia; monitor blood counts if used together.
• Oral hypoglycemic agents (sulfonylureas) and phenytoin: systemically absorbed sulfadiazine from Sibalyn may potentiate the effects of these drugs by displacing them from plasma protein binding sites; monitor for hypoglycemia or phenytoin toxicity, especially with large-surface-area burns.

The most common adverse effect with Sibalyn is:

• Transient leukopenia - usually appears 2-4 days after starting treatment and typically resolves spontaneously within 2-3 days even with continued therapy; more common with extensive burn surface area treated. Monitor white blood cell counts periodically, particularly in patients with large burns.

Less common effects include:

• Burning sensation, itching, rash, and other local skin reactions at the application site
• Skin discoloration (argyria-like discoloration with prolonged use) and skin necrosis
• Erythema multiforme
• Interstitial nephritis and other renal effects with extensive systemic absorption
• Fungal superinfection (low incidence)
• Delayed eschar separation

Rare but serious reactions associated with systemic sulfonamide absorption (agranulocytosis, aplastic anemia, thrombocytopenia, hemolytic anemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity) have been reported; discontinue and seek medical attention if signs of a serious reaction occur (fever, blistering, widespread rash, unusual bleeding or bruising, jaundice).

Pregnancy: Sibalyn is Pregnancy Category B in general use, but it is contraindicated in women at or near term due to the risk of kernicterus in the newborn (see Contraindications). Earlier in pregnancy, Sibalyn should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether topically applied Sibalyn is excreted in human breast milk. Because sulfonamides are excreted in breast milk and carry a theoretical risk of kernicterus in a nursing infant, caution is advised; consult a physician before using Sibalyn while breastfeeding, particularly with extensive body-surface-area application.

Use Sibalyn with caution in the following situations:

• G6PD deficiency: patients with glucose-6-phosphate dehydrogenase deficiency are at increased risk of hemolysis with sulfonamide exposure; use with caution and monitor.
• Extensive burn surface area: significant systemic absorption of sulfadiazine can occur when large areas are treated, increasing the risk of systemic sulfonamide-type adverse effects (blood dyscrasias, renal or hepatic effects). Monitor serum sulfa concentrations, complete blood counts, and renal and hepatic function periodically in patients with extensive burns.
• Renal or hepatic impairment: use with caution, as impaired elimination may increase systemic accumulation of absorbed sulfadiazine.
• Sterile technique: apply only to a properly cleansed and debrided wound using sterile technique to minimize risk of secondary infection; do not apply with bare hands.
• Not for ophthalmic use: avoid contact with the eyes.

Take exactly as prescribed by your physician; do not stop, extend, skip applications, or share this medicine with others without medical advice.

Overdose typically presents as excessive systemic absorption from application to very large burn surface areas, which may increase risk of sulfonamide-related systemic adverse effects (blood count changes, renal or hepatic effects). If accidental ingestion occurs or signs of systemic toxicity (unusual bruising/bleeding, jaundice, difficulty breathing, widespread rash) develop, discontinue Sibalyn immediately and seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube tightly closed and out of reach of children.

Pregnant women: contraindicated at or near term; use earlier in pregnancy only if clearly needed (see Pregnancy and Lactation).

Nursing mothers: use with caution; consult a physician (see Pregnancy and Lactation).

Neonates and premature infants (under 2 months): contraindicated due to kernicterus risk (see Contraindications).

Children over 2 months: Sibalyn may be used with the same application technique as in adults; monitor for leukopenia and systemic absorption effects, particularly with extensive burns.

Elderly patients: no specific dose adjustment is established; use with routine monitoring of renal function given greater likelihood of age-related renal impairment.

G6PD-deficient patients: use with caution due to hemolysis risk (see Precautions and Warnings).

Treatment with Sibalyn is continued until satisfactory wound healing has occurred or the burn site is ready for surgical grafting, as determined by the treating physician. Do not stop treatment early or extend it beyond what is prescribed without medical advice.

Topical sulfonamide antimicrobial (antibacterial) agent for burn/wound care.

Silver Sulfadiazine releases silver ions that bind to bacterial cell membrane and DNA components, disrupting bacterial cell wall structure and function and leading to bacterial cell death, while the sulfadiazine component inhibits bacterial folate synthesis, providing bacteriostatic activity. This combined mechanism gives Silver Sulfadiazine broad-spectrum activity against many gram-positive and gram-negative bacteria and some fungi.

Category B

Sibalyn is contraindicated in premature infants and newborns during the first 2 months of life because of the risk of kernicterus from bilirubin displacement by sulfonamide. In infants and children older than 2 months, safety and effectiveness are established for burn wound care using the same application technique as adults, with attention to monitoring for leukopenia and, in extensive burns, systemic sulfonamide absorption effects.